实用癌症杂志2024,Vol.39Issue(5) :713-716,720.DOI:10.3969/j.issn.1001-5930.2024.05.005

血清TAP、proGRP、cyfra21-1与Ⅲ~Ⅳ期NSCLC新辅助化疗疗效及预后的关系

Relationship Between Serum TAP,proGRP,cyfra21-1 and Curative Effect of Neoadjuvant Chemotherapy,Prognosis in Stage Ⅲ~Ⅳ NSCLC

高宇 石冰心 赵明娟
实用癌症杂志2024,Vol.39Issue(5) :713-716,720.DOI:10.3969/j.issn.1001-5930.2024.05.005

血清TAP、proGRP、cyfra21-1与Ⅲ~Ⅳ期NSCLC新辅助化疗疗效及预后的关系

Relationship Between Serum TAP,proGRP,cyfra21-1 and Curative Effect of Neoadjuvant Chemotherapy,Prognosis in Stage Ⅲ~Ⅳ NSCLC

高宇 1石冰心 1赵明娟1
扫码查看

作者信息

  • 1. 454000 焦作煤业(集团)有限责任公司中央医院
  • 折叠

摘要

目的 探讨血清肿瘤异常蛋白(TAP)、胃泌素释放肽前体(proGRP)、细胞角蛋白19片段(cyfra21-1)与Ⅲ~Ⅳ期非小细胞肺癌(NSCLC)新辅助化疗(NCT)疗效及预后的关系.方法 选取100例Ⅲ~Ⅳ期NSCLC患者为研究对象,所有患者均采用NCT治疗,根据疗效将患者分为有效组和无效组,比较不同疗效患者化疗前后TAP、proGRP、cy-fra21-1水平,分析化疗后TAP、proGRP、cyfra21-1水平对NSCLC患者NCT疗效的评估价值.所有患者均随访1年,分析化疗后TAP、proGRP、cyfra21-1表达水平与预后的关系.结果 化疗后,有效组TAP、proGRP、cyfra21-1水平低于无效组(P<0.05).ROC曲线结果显示,TAP评估NSCLC患者NCT疗效的AUC和截点值分别为0.739、178.18 μm2,proGRP评估NSCLC患者NCT疗效的AUC和截点值分别为0.810、52.21 ng/L,cyfra21-1评估NSCLC患者NCT疗效的AUC和截点值分别为0.775、7.70 μmol/L,联合评估NSCLC患者NCT疗效的AUC为0.913,高于单项诊断(P<0.05).TAP、pro-GRP、cyfra21-1高表达患者的1年生存率均低于低表达患者(P<0.05).结论 TAP、proGRP、cyfra21-1联合评估Ⅲ~Ⅳ期NSCLC患者NCT疗效具有较高价值,且其均与NSCLC患者预后密切相关.

Abstract

Objective To explore the relationship between serum tumor abnormal protein(TAP),gastrin releasing pep-tide precursor(proGRP),cytokeratin 19 fragment(cyfra21-1)and curative effect of neoadjuvant chemotherapy(NCT),prognosis in stage Ⅲ~Ⅳ non-small cell lung cancer(NSCLC).Methods 100 patients with stage Ⅲ~Ⅳ NSCLC undergoing NCT were enrolled as the research objects.According to different curative effect,they were divided into effective group and ineffective group.The levels of TAP,proGRP and cyfra21-1 in the 2 groups were compared before and after chemotherapy.The evaluation value of TAP,proGRP and cyfra21-1 for curative effect of NCT was analyzed.All patients were followed up for 1 year to analyze the rela-tionship between TAP,proGRP,cyfra21-1 and prognosis after chemotherapy.Results After chemotherapy,levels of TAP,proGRP and cyfra21-1 in effective group were lower than those in ineffective group(P<0.05).The results of ROC curves analysis showed that AUC and cut-off values of TAP,proGRP and cyfra21-1 for evaluating curative effect of NCT were(0.739,178.18 μm2),(0.810,52.21ng/L)and(0.775,7.70μmol/L),respectively.AUC of combined detection was 0.913,greater than that of single index(P<0.05).The 1-year survival rates in patients with high expressions of TAP,proGRP and cyfra21-1 were lower than those with low expressions(P<0.05).Conclusion TAP combined with proGRP and cyfra21-1 has high evaluation value for curative effect of NCT in patients with stage Ⅲ~Ⅳ NSCLC,and the three indexes are all closely related to prognosis.

关键词

非小细胞肺癌/Ⅲ~Ⅳ期/肿瘤异常蛋白/胃泌素释放肽前体/细胞角蛋白19片段/新辅助化疗/疗效/预后

Key words

Non-small cell lung cancer/Stage Ⅲ~Ⅳ/Tumor abnormal protein/Gastrin releasing peptide precursor/Cy-tokeratin 19 fragment/Neoadjuvant chemotherapy/Curative effect/Prognosis

引用本文复制引用

出版年

2024
实用癌症杂志
江西省肿瘤医院 江西省肿瘤研究所

实用癌症杂志

影响因子:1.241
ISSN:1001-5930
参考文献量20
段落导航相关论文